The safe application of lentiviral vectors in cell and gene therapy depends on precise risk mitigation strategies, particularly concerning replication-competent lentiviruses (RCLs). While these vectors have revolutionized modern medicine—powering breakthroughs in treating genetic disorders, immune cell engineering, and stem cell modification—the rare but significant safety challenges posed by RCLs demand crucial scientific rigor.
Read our new white paper to learn more about the complexity of RCL formation, their underlying mechanisms of recombination, and the critical risks they pose, including insertional mutagenesis, immunogenic responses, and potential interference with therapeutic outcomes. The white paper also explores state-of-the-art detection methodologies, from ddPCR to p24 antigen ELISA, alongside advancements in lentiviral vector design that enhance safety and reliability.
Our experts’ goal is to give you a deeper understanding of the science behind RCL detection and its importance in ensuring successful therapeutic applications.
Download our latest white paper to explore these insights and discover how SK pharmteco’s advanced RCL detection assays can seamlessly integrate into your therapeutic development pipeline. From rigorous testing to regulatory compliance, we’re here to support your journey toward safer, more effective cell and gene therapies.